Mangoceuticals Secures 180-Day Nasdaq Reprieve, Eyes Reverse Split to Maintain Listing
MGRX has more than doubled off its 52-week low of $0.162 on light trading volume (0.3× avg).
Summary
Nasdaq granted Mangoceuticals an additional 180 days to regain compliance with the minimum bid price requirement, and the company plans a reverse stock split if needed. The extension provides runway to close the pending reverse merger with Nuclea Energy.
Key Events · Legal and Risk Events · MGRX
-
Nasdaq Extension Granted
Nasdaq granted an additional 180-day compliance period until February 1, 2027, for the minimum bid price requirement, based on the company meeting other listing standards and its intent to cure via a reverse stock split.
-
Reverse Split on the Table
The company explicitly stated it will effect a reverse stock split if necessary to regain compliance, which would further dilute existing shareholders already facing a 96% reduction in ownership from the pending Nuclea Energy reverse merger.
-
Merger Context
The extension comes just days after announcing a definitive business combination agreement with Nuclea Energy, a private nuclear startup, in a deal that would leave current Mangoceuticals shareholders with only 4% of the combined entity.
-
Going Concern and Cash Pressure
The company's last 10-Q (May 2026) showed a sharp decline in cash, a growing accumulated deficit, and a going concern warning, underscoring the urgency of the merger and the listing extension.
Analysis · MGRX · Industrial Applications And Services
A critical 180-day extension from Nasdaq gives Mangoceuticals until February 1, 2027, to regain compliance with the $1.00 minimum bid price rule. The company has explicitly stated it will effect a reverse stock split if necessary to cure the deficiency. This development arrives just days after the announcement of a reverse merger with Nuclea Energy—a deal that would leave existing shareholders with only 4% of the combined company. While the extension buys time to complete the merger, the threat of a reverse split adds another layer of dilution risk for current holders.
How filings like this one have moved
In the 30 days to Sep 23, 2026, 29.1% of the 1683 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.32%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MGRX was trading at $0.44 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $7.9M. The 52-week trading range was $0.16 to $2.75. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.